Time to Initiation of Antiretroviral Therapy between 4 Weeks and 12 Weeks of Tuberculosis Treatment in HIV-1 Infected Patients: Results from the TIME Study

Weerawat Manosuthi1, Aroon Rueangniyomkul1, Wiroj Mankatitham1, Supeda Thongyen1, Sirirat Likanonsakul1, Pawita Suwanvattana1, Unchanha Thawornwan1, Busakorn Suntisuklappon1, Samruay Nilkamhang1, Somnuem Sungkanuparph2, for the TIME Study Team

Background: Optimal timing for initiation of antiretroviral therapy (ART) among HIV-1 infected patients with tuberculosis (TB) is limited in the setting of early ART at CD4 count of < 350 cells/mm³ in the middle income countries.

Methods: Thai HIV/TB co-infected patients who had CD4 count of < 350 cells/mm³ and diagnosed TB were randomized to initiate a once daily regimen of tenofovir/lamivudine/efavirenz at 4 weeks (group A) versus 12 weeks (group B) of TB treatment between 2009-2011. The primary endpoints were all-cause mortality and hospitalization according to an intent-to-treat analysis.

Results: Of 156 patients, 79 were in group A and 77 patients were in group B. Overall mean ± SD age was 38 ± 9 years; median (IQR) CD4 was 43 (47-106) cells/mm³; and median (IQR) HIV-1 RNA was 5.8 (5.4-6.3) log copies/mL. Eighty-three (53%) patients were diagnosed extra-pulmonary or disseminated TB. Eleven (7%) mortalities occurred in a totaling of 137 patient-years of follow-up. Seven percent (6/79, 8.76 per 100 patient-years) mortalities were in group A and 6% (5/77, 7.25 per 100 person-years) mortalities were in group B (OR=0.845, 95% CI=0.247-2.893, P > 0.99). The same trends were found in the subgroup of patients with baseline CD4 count < 100 vs 100 cells/mm³ (9% vs 11%, OR=1.239, 95%CI=0.338-4.542, P=0.753) and < 50 vs. ≥ 50 cells/mm³ (9% vs. 13%, OR=1.596, 95% CI=0.396-6.397, P=0.725). Twenty-eight (35%) patients in group A and 25 (32%) patients in group B were hospitalized (OR=1.142, 95%CI=0.588-2.217, P=0.737). Grade 2-4 adverse events related to ART and TB treatment were 39% (31/79) in group A and 34% (26/77) in group B (OR=1.267, 95%CI=0.659-2.435, P=0.509). In multivariate analysis adjusting for timing to initiating ART, ‘low albumin’ (OR=3.717, 95%CI=1.470-9.520, P=0.005).

1Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand.
2Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 14000, Thailand.

Received for publication: September 12, 2011.
95%CI=1.529-9.009, P=0.004) and ‘low baseline CD4 count’ (OR=1.014, 95%CI=0.999-1.029, P=0.061) were the independent predictors of all-cause mortality. Immune reconstitution inflammatory syndrome was more frequent in group A with an incidence of 8.86 vs. 5.02 per 100 person-months in group B over the first 6 months of ART (P=0.08).

**Conclusions:** In this study which conducted in a middle income country with early ART at CD4 count of <350 cells/mm³, survival advantage associated with very early initiating ART in HIV-infected patients with active TB was not found in any CD4 stratum. However, patients with low albumin and low baseline CD4 count were associated with higher risk of death.